These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15199445)

  • 1. Glycoprotein IIb/IIIa antagonists in acute coronary syndromes: where are we now?
    Maree A; Fitzgerald DJ
    Semin Vasc Med; 2003 Nov; 3(4):385-90. PubMed ID: 15199445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Which, when, how?].
    Juárez Herrera U
    Arch Cardiol Mex; 2001; 71 Suppl 1():S85-90. PubMed ID: 11565353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes.
    Harrington RA
    Semin Thromb Hemost; 2004 Dec; 30(6):639-47. PubMed ID: 15630670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
    Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
    Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [GP IIb/IIIa receptor antagonists--molecular and clinical aspects].
    Francuz T
    Postepy Hig Med Dosw; 2001; 55(3):419-32. PubMed ID: 11505641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of glycoprotein IIb/IIIa receptor inhibitors in acute coronary syndromes.
    Lepor NE
    Rev Cardiovasc Med; 2002; 3 Suppl 1():S3-S12. PubMed ID: 12439431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical studies on glycoprotein IIb/IIIa receptor antagonist].
    Rasmussen LH; Husted SE; Clemmensen PM; Gøtzsche CO; Helqvist S; Kristensen SD; Pedersen KE; Rasmussen K; Rasmussen S
    Ugeskr Laeger; 2000 Oct; 162(44):5944-7. PubMed ID: 11094564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
    Bolognese L
    Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trials with glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromes.
    Van de Werf F
    Thromb Haemost; 1997 Jul; 78(1):210-3. PubMed ID: 9198155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients.
    Tricoci P; Peterson ED
    J Interv Cardiol; 2006 Oct; 19(5):449-55. PubMed ID: 17020570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GPIIb-IIIa receptor inhibitors: what the interventional radiologist needs to know.
    Hofmann LV; Razavi M; Arepally A; Reginelli JP; Resar J; Geschwind JF; Corl F
    Cardiovasc Intervent Radiol; 2001; 24(6):361-7. PubMed ID: 11907740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
    O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
    J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The scientific basis for combined platelet and thrombin-directed pharmacotherapy in acute coronary syndromes.
    Becker RC
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E19-24;discussion E25-8. PubMed ID: 11156725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GPIIb/IIIa inhibitor-induced dethrombosis.
    Furman MI; Frelinger AL; Michelson AD
    J Thromb Thrombolysis; 2004 Aug; 18(1):11-7. PubMed ID: 15744548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.
    Kimmelstiel C; Badar J; Covic L; Waxman S; Weintraub A; Jacques S; Kuliopulos A
    Thromb Res; 2005; 116(1):55-66. PubMed ID: 15850609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycoprotein IIb/IIIa antagonists in acute coronary syndromes.
    Maree A; Fitzgerald D
    Haematologica; 2001 Nov; 86(11 Suppl 2):45-8. PubMed ID: 11926777
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting the use of glycoprotein IIb/IIIa antagonists--the diabetic patient.
    Meier-Ewert HK; Nesto RW
    Rev Cardiovasc Med; 2002; 3 Suppl 1():S20-7. PubMed ID: 12439433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.
    Collet JP; Montalescot G; Agnelli G; Van de Werf F; Gurfinkel EP; López-Sendón J; Laufenberg CV; Klutman M; Gowda N; Gulba D;
    Eur Heart J; 2005 Nov; 26(21):2285-93. PubMed ID: 15932908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: exploration of methods.
    Pieper KS; Tsiatis AA; Davidian M; Hasselblad V; Kleiman NS; Boersma E; Chang WC; Griffin J; Armstrong PW; Califf RM; Harrington RA
    Circulation; 2004 Feb; 109(5):641-6. PubMed ID: 14769687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous integrin alphavbeta3 and glycoprotein IIb/IIIa inhibition causes reduction in infarct size in a model of acute coronary thrombosis and primary angioplasty.
    Sakuma T; Sari I; Goodman CN; Lindner JR; Klibanov AL; Kaul S
    Cardiovasc Res; 2005 Jun; 66(3):552-61. PubMed ID: 15914120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.